Evidence map›Paper›PMID 28229827›Full record

ArticleClinical and experimental rheumatology

Anti-La positive, anti-Ro negative subset of primary Sjögren's syndrome: anti-La is a reality but is the disease?

Debashish Danda, Rohan Sharma, Dat Truong, Kristi A Koelsch, Biji T Kurien, Harini Bagavant, Umesh Deshmukh, C Erick Kaufman, David M Lewis, Donald U Stone and 4 more

Abstract read
In one paragraph

Article in Clinical and experimental rheumatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Prognostic value of Sjögren's syndrome autoantibodies.Journal of laboratory and precision medicine · 2018
    Article
  5. Article
  6. Classification criteria in Sjögren's syndrome.Annals of translational medicine · 2017
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Debashish DandaChristian Medical College, Vellore, India.
Rohan SharmaThe Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; and Medical Service, Department of Veterans Affairs Medical Center, Oklahoma City, USA.
Dat TruongThe Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, USA.
Kristi A KoelschThe Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; and Medical Service, Department of Veterans Affairs Medical Center, Oklahoma City, USA.
Biji T KurienThe Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; and Medical Service, Department of Veterans Affairs Medical Center, Oklahoma City, USA.
Harini BagavantThe Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, USA.
Umesh DeshmukhThe Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, USA.
C Erick KaufmanDepartment of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
David M LewisDepartment of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, USA.
Donald U StoneDepartment of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
Lida RadfarOral Diagnosis and Radiology Department, University of Oklahoma College of Dentistry, Oklahoma City, USA.
Astrid RasmussenThe Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, USA.
Kathy L SivilsThe Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, USA.
Robert H ScofieldThe Arthritis and Clinical Immunology Program, Oklahoma Med.Research Foundation; Dept.of Medicine, University of Oklahoma Health Sciences Center; and Medical Service, Dept.of Veterans Affairs Medical Center, Oklahoma City, USA. hal-scofield@omrf.ouhsc.edu.
University of Oklahoma · USUniversity of Oklahoma Health Sciences Center · USChristian Medical College & Hospital · IN

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI JENNIFER DAVID PECK · 2013 to 2026
$68.2M
Pathogenic B Cells in Sjogren's SyndromeP50AR060804 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI SCOFIELD, ROBERT HAL · 2011 to 2015
$7.9M
SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI CHAKRAVARTY, ELIZA F · 2007 to 2017
$6.7M
Pre-Clinical Studies to Identify SLE Therapeutic TargetsU19AI082714 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2009 to 2018
$6.2M
Sjogren's Syndrome Pathogenic AutoantibodiesR01DE028001 · NIDCR · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI SCOFIELD, ROBERT HAL · 2019 to 2023
$1.7M
BLRD VA I01 BX001451NIAID NIH HHS U19 AI082714NIAMS NIH HHS P30 AR053483NIAMS NIH HHS P50 AR060804NIDCR NIH HHS R01 DE028001NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

objectivesTo characterise the serological and clinical findings in primary Sjögren's syndrome in which anti-La was found without anti-Ro. We hypothesised that a significant portion of these are falsely negative for anti-Ro60.

methodsTwenty-nine sera from primary Sjögren's syndrome patients were tested for antibodies directed against La and Ro. Anti-La was detected using bovine La treated with or without DNAase and RNAase to identify potential false positivity. Anti-Ro60 antibodies were detected using HEp-2000 substrate (in which cells are transfected with human Ro60) and HEp-2 substrate. Anti-Ro60 and Ro-52 were also tested by in vitro transcription/translation followed by immunoprecipitation assay.

resultsAll 29 sera bound La, even after treatment with DNAase and RNAase. Of the 29 sera, 25 were unequivocally negative on HEp-2000 (1:40 dilution). Four samples were anti-Ro60 positive with a speckled pattern, three of the four at 1:320 dilution. Thus, false negative anti-Ro60 exists in a small fraction (14%) of the Ro-negative/La-positive primary Sjögren's patients. However, all the samples were negative for Ro60 and Ro52 by in vitro immunoprecipitation assay. Clinically these patients tended not to have salivary gland pathology characteristic of Sjögren's syndrome.

conclusionsWe found only a small fraction of Ro negative/La positive sera to show positive HEp-2000 pattern. These subjects did not have characteristic findings on pathological examination of minor salivary glands, suggesting these subjects have a process distinct from Sjögren's syndrome.

Indexed as

AutoimmunityAdultAntibodies, AntinuclearBiomarkersEnzyme-Linked Immunosorbent AssayFalse Negative ReactionsHumansImmunoprecipitationMaleMiddle AgedPredictive Value of TestsReproducibility of ResultsSerologic TestsSjogren's SyndromeAntibodies, AntinuclearBiomarkersSS-A antibodiesSS-B antibodies

Identifiers

PMID28229827
PMCPMC12668385
OpenAlexW2758900089

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.